Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in ... to the global onco ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Royalty Pharma ... s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was ...

With Unloxcyt, an FDA-approved PD-L1 therapy for advanced cutaneous squamous cell carcinoma, the acquisition is slated to bolster Sun’s oncology-dermatology franchise, Dilip Shanghvi ...

Sun Pharmaceutical Industries Limited on Monday announced that it will acquire Checkpoint, an immunotherapy and targeted oncology company. According to the company’s exchange filing, Checkpoint ...

pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma ...

to Sun Pharma's global franchise. The deal will be made through an upfront cash payment of $4.10 per common share, a premium of about 66% to Checkpoint's last close on Friday, the Indian pharma ...